Browsing by Author "Ozatli D."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
    (Elsevier Inc., 2022) Akpinar S.; Dogu M.H.; Celik S.; Ekinci O.; Hindilerden I.Y.; Dal M.S.; Davulcu E.A.; Tekinalp A.; Hindilerden F.; Ozcan B.G.; Hacibekiroglu T.; Erkurt M.A.; Bagci M.; Namdaroglu S.; Korkmaz G.; Bilgir O.; Cagliyan G.A.; Ozturk H.B.A.; Serin I.; Tiryaki T.O.; Ozatli D.; Korkmaz S.; Ulas T.; Eser B.; Turgut B.; Altuntas F.
    Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ≥ grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atrial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare during the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. © 2021 Elsevier Inc.
  • No Thumbnail Available
    Item
    International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report
    (Elsevier Ltd, 2023) Ozatli D.; Giden A.O.; Erkurt M.A.; Korkmaz S.; Basci S.; Ulas T.; Turgut B.; Yigenoglu T.N.; Hacibekiroglu T.; Basturk A.; Dal M.S.; Namdaroglu S.; Hindilerden F.; Hacioglu S.K.; Cagliyan G.A.; Ilhan G.; Kacmaz M.; Uysal A.; Merter M.; Ekinci O.; Dursun F.E.; Tekinalp A.; Demircioglu S.; Sincan G.; Acik D.Y.; Akdeniz A.; Ucar M.A.; Yeral M.; Ciftciler R.; Teke H.U.; Umit E.G.; Karakus A.; Bilen Y.; Yokus O.; Albayrak M.; Demir C.; Okan V.; Serefhanoglu S.; Kartı S.; Ozkurt Z.N.; Eser B.; Aydogdu I.; Kuku I.; Cagirgan S.; Sonmez M.; Ozet G.; Altuntas F.
    Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications. © 2023 Elsevier Ltd
  • No Thumbnail Available
    Item
    Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    (Taylor and Francis Ltd., 2023) Bakırtaş M.; Dal M.S.; Yiğenoğlu T.N.; Giden A.O.; Serin I.; Başcı S.; Kalpakci Y.; Korkmaz S.; Ekinci O.; Albayrak M.; Basturk A.; Ozatli D.; Dogu M.H.; Hacıbekiroglu T.; Çakar M.K.; Ulas T.; Miskioglu M.; Gulturk E.; Eser B.; Altuntas F.
    A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).